The Danish global healthcare company Novo Nordisk announced this week an investment of 2 billion dollars for new facilities both in North Carolina, US, and Måløv, Denmark.
The new investment in infrastructures is expected to improve the Danish company production capacity of their diabetes medicines.
Novo Nordisk is planning to establish one new production facility in the Danish location of Måløv. The plant will create an estimation of a hundred new jobs, in addition to the 250 people the company currently employs producing tablets for hormone replacement therapy.
The new facilities in Clayton, North Carolina, will also generate 700 new production and engineering jobs. The US building will produce active pharmaceutical ingredients (API) to use in insulin products.
The US is a major market for the Danish company and the plant in Clayton assembles insulin products like Flexpen and FlexTouch.
“With the new plant in Clayton (North Carolina) and continuous investments in our current API production plants in Kalundborg, Denmark, we will have sufficient API capacity for diabetes products well into the next decade,” said Henrik Wulff, executive vice president and head of Product Supply at Novo Nordisk.
Novo Nordisk is also expected to make investments in their largest plant located in Kalundborg, Denmark. The facilities were established in 1969, and today more than 2800 people are employed there.
The two new production facilities of Clayton and Måløv are expected to be fully operative in 2020.